Nanobiotix S.A. (NBTX) stock
Close on Nov 12, 2026Market cap $1.56BP/E –Yield –
Nanobiotix S.A. reported revenue of €32.59M for fiscal 2025. Free cash flow was -€33.96M. At the latest close the market valued the company at €1.40B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- €1.40B
- P/E ratio
- –
- Price to sales
- 42.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.43%
Fundamentals
- Revenue
- €32.59M
- Net income
- -€23.96M
- EPS, diluted
- -0.50 EUR
- Free cash flow
- -€33.96M
Trading
- Previous close
- $32.95
- Open
- $31.93
- Day's range
- $31.28 – $33.35
- Volume
- 171,116
- Average volume (20 days)
- 151,759
- Beta (5 years)
- 0.48
- RSI (14 days)
- 56.8
- Volatility (1 year)
- 85.0%
- Relative volume
- 1.16×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NBTX | S&P 500 | Difference | NBTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +37.8% | -2.7% | +40.5 pts | ||
| 3 months | -18.2% | -1.7% | −16.5 pts | ||
| Year to date | +39.5% | +11.9% | +27.6 pts | ||
| 1 year | +49.5% | +12.0% | +37.5 pts | ||
| 3 years | +451.3% | +78.2% | +373.1 pts | +76.7% | +21.2% |
| 5 years | +229.8% | +73.2% | +156.5 pts | +27.0% | +11.6% |
Nine years at a glance
Fiscal years 2017 to 2025, EUR
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Nanobiotix filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Nanobiotix
Pharmaceutical Preparations
Nanobiotix S.A. is a clinical-stage biotechnology company that develops physics-based nanotherapeutics designed to treat cancer and other diseases. The company operates through three main technology platforms: a nanoradioenhancer platform, a nanoprimer platform, and a neurological disease platform. Its lead product candidate, JNJ-1900 (also known as NBTXR3), is an intratumorally injected suspension of hafnium oxide nanoparticles designed to amplify the tumor-destroying effect of radiation therapy in solid tumors, including head and neck and lung cancers. The company serves cancer patients requiring radiotherapy, collaborating with pharmaceutical corporations and medical research institutions to conduct clinical evaluations and commercialization.
Company profile, executives and historyNanobiotix stock: common questions
What is Nanobiotix's stock price?
NBTX closed at $32.25 on Nov 12, 2026, down 2.12% on the day.
What is Nanobiotix's market cap?
Nanobiotix was worth $1.56B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NBTX's P/E ratio?
Nanobiotix lost money over fiscal 2025 (diluted EPS -0.50 EUR), so it has no meaningful P/E ratio.
How much revenue does Nanobiotix make?
Nanobiotix reported revenue of €32.59M for fiscal 2025.
Does Nanobiotix pay a dividend?
No. Nanobiotix has not paid a cash dividend over the last twelve months.
How has NBTX stock performed over the past year?
Including dividends, NBTX returned +49.5% over the past year, against +12.0% for the S&P 500.
Who are Nanobiotix's competitors?
Companies most similar to Nanobiotix by business, industry and size include XLO, JANX, PYXS, ZNTL, CBIO.
See a number that looks wrong?